Genomic Health announces presentation of two additional Oncotype DX clinical outcomes
 

Genomic Health, Inc. today announced that, in addition to the positive five-year results from a group of patients with low Oncotype DX Recurrence Score results from the watershed ECOG-ACRIN Cancer Research Group's TAILORx (Trial Assigning IndividuaLized Options for Treatment [Rx]) study, sponsored by the National Cancer Institute (NCI), published today in The New England Journal of Medicine, two additional positive international Oncotype DX clinical outcomes studies were presented at the 2015 European Cancer Congress (ECC2015).

More...